Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various PH Levels

Overview

Journal Adv Ther

Date 2015 May 9

PMID 25951927

Citations 10

Authors

Adeyinka Abinusawa

Srini Tenjarla

Affiliations

Soon will be listed here.

Abstract

Introduction: Oral formulations of 5-aminosalicylic acid (5-ASA) for treatment of ulcerative colitis have been developed to minimize absorption prior to the drug reaching the colon. In this study, we investigate the release of 5-ASA from available oral mesalamine formulations in physiologically relevant pH conditions.

Methods: Release of 5-ASA from 6 mesalamine formulations (APRISO®, Salix Pharmaceuticals, Inc., USA; ASACOL® MR, Procter & Gamble Pharmaceuticals UK Ltd.; ASACOL® HD, Procter & Gamble Pharmaceuticals, USA; MEZAVANT XL®, Shire US Inc.; PENTASA®, Ferring Pharmaceuticals, Ltd., UK; SALOFALK®, Dr. Falk Pharma UK Ltd.) was evaluated using United States Pharmacopeia apparatus I and II at pH values of 1.0 (2 h), 6.0 (1 h), and 6.8 (8 h). Dissolution profiles were determined for each formulation, respectively.

Results: Of the tested formulations, only the PENTASA formulation demonstrated release of 5-ASA at pH 1.0 (48%), with 56% cumulative release after exposure to pH 6.0 and 92% 5-ASA release after 6-8 h at pH 6.8. No other mesalamine formulation showed >1% drug release at pH 1.0. The APRISO formulation revealed 36% 5-ASA release at pH 6.0, with 100% release after 3 h at pH 6.8. The SALOFALK formulation revealed 11% 5-ASA release at pH 6.0, with 100% release after 1 h at pH 6.8. No 5-ASA was released by the ASACOL MR, ASACOL HD, and MEZAVANT XL formulations at pH 6.0. At pH 6.8, the ASACOL MR and ASACOL HD formulations exhibited complete release of 5-ASA after 4 and 2 h, respectively, and the MEZAVANT XL formulation demonstrated complete 5-ASA release over 6-7 h.

Conclusion: 5-Aminosalicylic acid release profiles were variable among various commercially available formulations.

Funding: Shire Development LLC.

Citing Articles

Design, Development, and Optimisation of Smart Linker Chemistry for Targeted Colonic Delivery-In Vitro Evaluation.

Abd-Ellah H, Mudududdla R, Carter G, Baell J Pharmaceutics. 2023; 15(1).

PMID: 36678931 PMC: 9860859. DOI: 10.3390/pharmaceutics15010303.

Colon-targeting mutual prodrugs of 5-aminosalicylic acid and butyrate for the treatment of ulcerative colitis.

Yan Y, Sun J, Xie X, Wang P, Sun Y, Dong Y RSC Adv. 2022; 8(5):2561-2574.

PMID: 35541446 PMC: 9077470. DOI: 10.1039/c7ra13011b.

Additive Manufacturing of Oral Tablets: Technologies, Materials and Printed Tablets.

Abaci A, Gedeon C, Kuna A, Guvendiren M Pharmaceutics. 2021; 13(2).

PMID: 33504009 PMC: 7912000. DOI: 10.3390/pharmaceutics13020156.

Effect of acid-reducing agents on clinical relapse in ulcerative colitis with pH-dependent-released 5-aminosalicylic acid: a multicenter retrospective study in Japan.

Shimodaira Y, Onochi K, Watanabe K, Takahashi S, Fukuda S, Watanabe N Intest Res. 2020; 19(2):225-231.

PMID: 32806877 PMC: 8100376. DOI: 10.5217/ir.2020.00023.

Protective Effect of Asacol in Combination with Pantoprazole in Ulcerative Colitis Patients Who Defecate Asacol Tablets Intactly: A Clinical Trial Study.

Bashiri H, Bozorgomid A Clin Exp Gastroenterol. 2020; 13:47-51.

PMID: 32158250 PMC: 6986402. DOI: 10.2147/CEG.S225675.

References

Kornbluth A, Sachar D . Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010; 105(3):501-23. DOI: 10.1038/ajg.2009.727. View

Layer P, Goebell H, Keller J, Dignass A, Klotz U . Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology. 1995; 108(5):1427-33. DOI: 10.1016/0016-5085(95)90691-6. View

Sutherland L, MacDonald J . Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006; (2):CD000543. DOI: 10.1002/14651858.CD000543.pub2. View

Adams S, Bornemann P . Ulcerative colitis. Am Fam Physician. 2013; 87(10):699-705. View

Lichtenstein G, Kamm M . Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa. Aliment Pharmacol Ther. 2008; 28(6):663-73. DOI: 10.1111/j.1365-2036.2008.03751.x. View

Spencer J, Gao Z, Moore T, Buhse L, Taday P, Newnham D . Delayed release tablet dissolution related to coating thickness by terahertz pulsed image mapping. J Pharm Sci. 2007; 97(4):1543-50. DOI: 10.1002/jps.21051. View

Sandborn W, Kamm M, Lichtenstein G, Lyne A, Butler T, Joseph R . MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2007; 26(2):205-15. DOI: 10.1111/j.1365-2036.2007.03361.x. View

Fallingborg J . Intraluminal pH of the human gastrointestinal tract. Dan Med Bull. 1999; 46(3):183-96. View

DInca R, Paccagnella M, Cardin R, Pathak S, Baldo V, Giron M . 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis. World J Gastroenterol. 2013; 19(34):5665-70. PMC: 3769903. DOI: 10.3748/wjg.v19.i34.5665. View

10.

Ligumsky M, Karmeli F, Sharon P, ZOR U, Cohen F, Rachmilewitz D . Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology. 1981; 81(3):444-9. View

11.

Rasmussen S, Bondesen S, Hvidberg E, Hansen S, Binder V, Halskov S . 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982; 83(5):1062-70. View

12.

Kane S, Katz S, Jamal M, Safdi M, Dolin B, Solomon D . Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. Inflamm Bowel Dis. 2011; 18(6):1026-33. DOI: 10.1002/ibd.21841. View

13.

Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R . Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011; 60(5):571-607. DOI: 10.1136/gut.2010.224154. View

14.

DHaens G, Sandborn W, Barrett K, Hodgson I, Streck P . Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis. Am J Gastroenterol. 2012; 107(7):1064-77. DOI: 10.1038/ajg.2012.103. View

15.

Shafii A, Chowdhury J, Das K . Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats. Am J Gastroenterol. 1982; 77(5):297-9. View

16.

Travis S, Stange E, Lemann M, Oresland T, Bemelman W, Chowers Y . European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis. 2010; 2(1):24-62. DOI: 10.1016/j.crohns.2007.11.002. View

17.

Tenjarla S, Abinusawa A . In-vitro characterization of 5-aminosalicylic acid release from MMX mesalamine tablets and determination of tablet coating thickness. Adv Ther. 2010; 28(1):62-72. DOI: 10.1007/s12325-010-0087-5. View

18.

Brunner M, Assandri R, Kletter K, Tschurlovits M, Corrado M, Villa R . Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther. 2003; 17(3):395-402. DOI: 10.1046/j.1365-2036.2003.01445.x. View

19.

Lichtenstein G, Kamm M, Sandborn W, Lyne A, Joseph R . MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther. 2008; 27(11):1094-102. DOI: 10.1111/j.1365-2036.2008.03688.x. View

20.

Vernia P, Caprilli R, Latella G, Barbetti F, Magliocca F, Cittadini M . Fecal lactate and ulcerative colitis. Gastroenterology. 1988; 95(6):1564-8. DOI: 10.1016/s0016-5085(88)80078-7. View